TITLE

Postmarketing surveillance of sofosbuvir in Egypt

PUB. DATE
April 2015
SOURCE
Reactions Weekly;Apr2015, Vol. 1547 Issue 1, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the clarification of the Technical Committee at the Central Administration of Pharmaceutical Affairs on the requirements for postmarketing surveillance of sofosbuvir for hepatitis C in Egypt.
ACCESSION #
102170947

 

Related Articles

  • Guideline: New HCV Drugs Should Go to Sickest Patients. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;9/17/2014, Vol. 312 Issue 11, p1084 

    The article discusses a guideline for hepatitis C virus (HCV) drugs published by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America in 2014. Topics covered include the estimated number of individuals in the U.S. with chronic hepatitis C...

  • Acute Hepatitis C Infection with Unclear Route of Transmission. Cheng, J.; Jiang, S. W.; Zhang, L. Z.; Zhou, Z. S.; Li, J. B.; Li, X.; Sun, Q. L. // West Indian Medical Journal;Mar2012, Vol. 61 Issue 2, p202 

    A 43-year old man acquired acute hepatitis C virus (HCV) infection with unclear route of transmission. There were no known sexual or other risk factors for HCV acquisition. Phylogenetic analysis confirmed that the case was infected with identical genotype 1b strain. After symptomatic treatment...

  • Advancing Service Integration in Opioid Treatment Progams for the Care and Treatment of Hepatitis C Infection. Kresina, Thomas F.; Lubran, Robert; Clark, H. Westley; McCance-Katz, Elinore F. // International Journal of Clinical Medicine;Jan2014, Vol. 5 Issue 3, p118 

    It is estimated that approximately 200 million people globally are infected with the hepatitis C virus and that roughly half of these people live in Asia. Without treatment, it is estimated that roughly twenty percent of those infected with hepatitis C virus progress to chronic liver disease,...

  • Interferon Alfacon-1 Injection.  // AHFS Consumer Medication Information;Aug2020, p1 

    Your doctor has ordered interferon alfacon-1 to help treat your hepatitis C infection. The drug will be injected under your skin (subcutaneously) three times a week. Your healthcare provider will show you what to do. Interferon alfacon-1 is a synthetic interferon that helps to prevent the...

  • High Prevalence of HIV, HCV and Tuberculosis and Associated Risk Behaviours among New Entrants of Methadone Maintenance Treatment Clinics in Guangdong Province, China. Zhang, Lei; Zhang, Di; Chen, Wen; Zou, Xia; Ling, Li // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Background:Methadone maintenance treatment (MMT) has been available in Guangdong province, China since 2006. This study aims to estimate the prevalence levels of HIV, Hepatitis C (HCV), Tuberculosis (TB) and their co-infections and associated demographic and risk behaviours among MMT entrants....

  • Post-marketing surveillance. Culliton, Barbara J.; Waterfall, Wallace K. // British Medical Journal;5/10/1980, Vol. 280 Issue 6224, p1175 

    Focuses on the system for monitoring the use and effects of prescription drugs following marketing strategy in the United States. Methods of post-marketing surveillance of pharmaceutical; Emphasis of the Food and Druf Administration on pre-marketing phases of drug development; Creation of the...

  • Best candidates for PCSK9 inhibitors. EDLIN, MARI // Managed Healthcare Executive;Feb2016, Vol. 26 Issue 2, p41 

    The article discusses the move of pharmacy benefits managers (PBMs) and insurers to test the formularies of new hepatitis C drugs to be placed on the PCSK9 drug lists. The Food and Drug Administration (FDA) has approved the self-injectable Sanofi-Regeneron's Praluent (alirocumab) and Amgen's...

  • Romark and Chugai sign licensing agreement.  // PharmaWatch: Biotechnology;Apr2009, Vol. 8 Issue 4, p18 

    The article reports on the signing of a licensing agreement by Romark Laboratories LC and Chugai Pharmaceutical Co. Ltd. for the development and commercialization of nitazoxanide for chronic hepatitis C in Japan. It is noted that Chugai Pharmaceutical Co. Ltd. will make additional payments based...

  • DID YOU KNOW?  // HealthLeaders Magazine;Mar2009, Vol. 12 Issue 3, p14 

    The article looks at the higher spending of Americans on prescription drugs compared to other industrialized countries in Europe. According to a report, patients in the U.S. spend each year $98 billion on medications which are more than those of other countries. Also included is an overview of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics